


1

Supplemental Data**2 Supplemental Figures****3 Supplemental Figure S1**

4

5 PPAR α is low-expressed in t-FL samples compared to normal CD19 $^+$ B cells from
6 healthy donors.

7

8

9

10

11

12

13

14

15


16

17

18

19

20 **Supplemental Figure S2**



21

22 The body weights of the CDX mice of RL (**A**) and SC-1 (**B**) cells did not significantly
23 change after administration of chiglitazar (15 mg/kg).

24

25

26

27

28

29

30

31

32


33

34

35

36

37 **Supplemental Figure S3**



38


39 Representative images of the cell cycle of RL (A), SC-1 (B), and Karpas 422 cells (C)
40 after treatment with DMSO or chiglitazar (5 μ M, 10 μ M, 20 μ M) were analyzed by PI
41 staining.

42

43

44

45 **Supplemental Figure S4**



46

47 Real-time PCR analysis was used to analyze the effects of chiglitazar treatment (10 μ M,
48 20 μ M) for 24 h on the mRNA levels of RL, SC-1, and Karpas 422 cell cycle-related
49 genes (*FOXM1*, *C-MYC*, *cyclin B1*, *cyclin D1*, and *cyclin E1*).

50

51


52

53

54

55

56

57 **Supplemental Figure S5****B**

Matrix ID	Name	Score	Relative score
MA1147.1	MA1147.1.NR4A2::RXRA	9.10522	0.826577122
MA1146.1	MA1146.1.NR1H4::RXRA	10.3195505	0.825526832
MA1146.1	MA1146.1.NR1H4::RXRA	10.020849	0.820851085
MA1147.1	MA1147.1.NR4A2::RXRA	8.082063	0.812364993
MA0159.1	MA0159.1.RARA::RXRA	10.386636	0.809478649

58

59 The PPAR α binding site in the promoter region of *FOXM1* was predicted using the
 60 Jasper website. Motif analysis of the accessible promoter region (**A**) and relative scores
 61 for different regions (**B**).

62

63

64

65

66

67


68

69

70

71

72 **Supplemental Figure S6**



73

74 Expression of *FOXM1* and its target genes (*C-MYC*, *CyclinB1*, *CyclinD1*, *CyclinE1*,
 75 *CyclinE2*, *CDK1* and *CDK2*) was assessed by real-time PCR in *FOXM1*-knockdown
 76 RL (A) and SC-1 cells (B).

77

78


79

80

81

82

83 Supplemental Figure S7



85 Representative images of the cell cycle in *FOXMI*-knockdown (**A**) and *FOXMI*-
86 overexpressed (**B**) RL and SC-1 cells were analyzed using PI staining.

87

88

89

90

91

92

93

94

95

96

97

98

99

100

101

102


103

104

105

106

107 **Supplemental Figure S8**



108

109 The t-FLPDX cells are identified by flow cytometry staining using human CD10, CD19
110 and CD20 antibodies.

111

112

113

114

115

116

117

118

Supplementary Tables120 **Supplementary Table 1.** Clinical characteristics of FL and t-FL patients.**Clinical characteristics of FL and t-FL patients**

Patient No	Clinical diagnosis	Stage	relapse	Age	Gender
1	Follicular lymphoma	unknown	no	64	F
2	Follicular lymphoma	III	no	58	M
3	Follicular lymphoma	IV	yes	54	F
4	Follicular lymphoma	IIIA	yes	77	M
5	DLBCL	IV	no	48	M
6	DLBCL	IIIA	no	74	M
7	DLBCL	unknown	no	60	M
8	DLBCL	IVA	no	66	M
9	DLBCL	IVA	yes	43	F
10	DLBCL	IIIA	no	57	M
11	Follicular lymphoma	IVA	no	51	F
12	DLBCL	unknown	yes	70	M
13	Classic Hodgkin lymphoma, small lymphocytic lymphoma	unknown	no	58	F
14	Burkitt lymphoma	IV	no	46	F
15	Mantle cell lymphoma	unknown	no	60	F
16	small lymphocytic lymphoma	unknown	no	74	F
17	DLBCL	IIIB	no	61	F
18	DLBCL	IVA	no	75	F
19	Follicular lymphoma	unknown	no	54	M
20	Follicular lymphoma	IVA	no	69	M
21	DLBCL	IVB	no	73	F
22	DLBCL	IV	no	39	F
32	DLBCL	IIIB	no	61	F
24	DLBCL	IIIA	no	59	F
25	DLBCL	IIIA	no	58	F
26	DLBCL	unknown	no	58	F
27	Follicular lymphoma	IIIB	no	47	F
28	DLBCL	IVA	no	55	F
29	DLBCL	IVA	no	66	M

Supplementary Table 2. The primers used for the quantitative qPCR.

Name	Sequence	
	Forward	Reverse
GAPDH	GGAGCGAGATCCCTCCAAAAT	GGCTGTTGTCACTTCTCATGG
FOXM1	AGACCTGTGCAGATGGTGAG	CTGATGGTCTCG AAGGCTCC
C-MYC	CGTCTCCACACATCAGCACAA	TCTTGGCAGCAGGATAGTCCTT
<i>cyclin A2</i>	TTCACACATACCTTAGGGAAATGG	AGCCAAATGCAGGGTCTCAT
<i>cyclin D1</i>	CATCTACACCGACAACCTCCATC	GTTCAATGAAATCGTGCAGGG
<i>cyclin E1</i>	GTCCTGGCTGAATGTATACTGC	CCCTATTGTTAGACAACAT
<i>cyclin E2</i>	AACTACCCAGGATGTCAAAAAAAGA	ATCAGGCAAAGGTGAAGGATTAATA
CDK1	TTCAGGATGTGCTTATGCAGGA	CTTCTAGAGTGACAAACACAATCCC
CDK2	CCGCCTGGACACTGAGACT	GTGGAGGACCCGATGAGA
CDC25	CTACTCATCCCTGCCCTCTG	TCAAACCCGTAACACAGCAA
<i>cyclin B1</i>	TAAGATTGGAGAGGTTGATGCGA	CCAGGTGCTGCATAACTGGA
<i>cyclin B2</i>	ATGTGACTATTAGGCGAACT	AGAGCAAGGCATCAGAAA

125

126

127

128

129

130

131

132

133

134 **Supplementary Table 3.** The IC₅₀ values of RL, SC-1 and Karpas 422 cells treated
135 with chiglitazar

Cell lines	Agents	24 h		48 h	
		IC50 (μM)	95% Confidence intervals (μM)	IC50 (μM)	95% Confidence intervals (μM)
RL	Chiglitazar	34.74	33.54 to 36.12	29.32	27.63 to 31.26
SC-1	Chiglitazar	37.97	35.17 to 41.53	25.35	23.25 to 27.69
Karpas 422	Chiglitazar	41.76	38.96 to 45.30	19.22	17.88 to 20.68

136

137

138

139

140

141

142

143